Evidence map›Paper›PMID 36634978›Full record

ArticleBMJ open diabetes research & care2023

Diabetes with poor-control HbA1c is cardiovascular disease 'risk equivalent' for mortality: UK Biobank and Hong Kong population-based cohort study.

Eric Yuk Fai Wan, Esther Yee Tak Yu, Ivy Lynn Mak, Hin Moi Youn, Kam Suen Chan, Esther W Y Chan, Ian C K Wong, Cindy Lo Kuen Lam

Registry-linked trialAbstract read
In one paragraph

Article in BMJ open diabetes research & care, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06674161 (The Impact of Type 2 Diabetes Mellitus on Cardiovascular Events in Saudi Arabia Now and Future), which is not on this map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06674161 not yet recruitingnot on this mapstarted 2024, after this paper: background citation

The Impact of Type 2 Diabetes Mellitus on Cardiovascular Events in Saudi Arabia Now and Future

TypeobservationalSponsorKing Faisal Specialist Hospital & Research CenterRan2024 to 2030Enrolled80ConditionsMortality of Patients with CVD, Mortality of Patients with CVD and T2DM, Mortality of Patients with T2DM, Mortality of Patients with Neither
3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Eric Yuk Fai WanDepartment of Family Medicine and Primary Care, The University of Hong Kong, Hong Kong, Hong Kong ytyu@hku.hk yfwan@hku.hk.ORCID 0000-0002-6275-1147
Esther Yee Tak YuDepartment of Family Medicine and Primary Care, The University of Hong Kong, Hong Kong, Hong Kong ytyu@hku.hk yfwan@hku.hk.
Ivy Lynn MakDepartment of Family Medicine and Primary Care, The University of Hong Kong, Hong Kong, Hong Kong.
Hin Moi YounDepartment of Family Medicine and Primary Care, The University of Hong Kong, Hong Kong, Hong Kong.
Kam Suen ChanDepartment of Family Medicine and Primary Care, The University of Hong Kong, Hong Kong, Hong Kong.
Esther W Y ChanCentre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, The University of Hong Kong, Hong Kong, Hong Kong.
Ian C K WongCentre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, The University of Hong Kong, Hong Kong, Hong Kong.
Cindy Lo Kuen LamDepartment of Family Medicine and Primary Care, The University of Hong Kong, Hong Kong, Hong Kong.

Funding

Medical Research Council MC_PC_17228Wellcome Trust
6 · The paper itself

Abstract

introductionType 2 diabetes mellitus (T2DM) has traditionally been considered a coronary heart disease 'risk equivalent' for future mortality, but significant heterogeneity exists across people with T2DM. This study aims to determine the risk of all-cause mortality of patients with cardiovascular disease (CVD) and T2DM in UK and Hong Kong, with stratifications for hemoglobin A1 (HbA1c) concentrations, compared with those without CVD and diabetes mellitus. RESEARCH DESIGN AND

methodsThis is a retrospective cohort study of 3 839 391 adults from Hong Kong and a prospective cohort study of 497 779 adults from the UK Biobank. Individuals were divided into seven disease groups: (1) no T2DM and CVD, (2) T2DM only with HbA1c <7%, (3) T2DM only with HbA1c 7%-7.9%, (4) T2DM only with HbA1c 8%-8.9%, (5) T2DM only with HbA1c ≥9%, (6) CVD only, and (7) T2DM and CVD. Differences in all-cause mortality between groups were examined using Cox regression.

resultsAfter around 10 years of median follow-up, 423 818 and 19 844 deaths were identified in the Hong Kong cohort and UK Biobank, respectively. Compared with individuals without T2DM and CVD, the adjusted HR for all-cause mortality in the other six disease groups for the Hong Kong cohort was 1.25 (95% CI 1.23 to 1.27) for T2DM only with HbA1c <7%, 1.21 (95% CI 1.19 to 1.23) for T2DM only with HbA1c 7%-7.9%, 1.36 (95% CI 1.33 to 1.39) for T2DM only with HbA1c 8%-8.9%, 1.82 (95% CI 1.78 to 1.85) for T2DM only with HbA1c ≥9%, 1.37 (95% CI 1.36 to 1.38) for CVD only, and 1.83 (95% CI 1.81 to 1.85) for T2DM and CVD, and for the UK Biobank the HR was 1.45 (95% CI 1.33 to 1.58), 1.50 (95% CI 1.32 to 1.70), 1.72 (95% CI 1.43 to 2.08), 2.51 (95% CI 2.05 to 3.08), 1.67 (95% CI 1.59 to 1.75) and 2.62 (95% CI 2.42 to 2.83), respectively. This indicates that patients with T2DM had an increased risk of mortality compared with those without T2DM and CVD, and in those with HbA1c ≥9% an even higher risk than people with CVD.

conclusionsPatients with T2DM with poor HbA1c control (8%-8.9% and ≥9%) were associated with similar and higher risk of mortality compared with patients with CVD, respectively. Optimal HbA1c, controlled for risk reduction and prevention of mortality and complications in diabetes management, remains important.

Indexed as

Cardiovascular DiseasesDiabetes Mellitus, Type 2AdultBiological Specimen BanksCohort StudiesGlycated HemoglobinHong KongHumansProspective StudiesRetrospective StudiesUnited KingdomGlycated HemoglobinGlycemic ControlMortalityType 2 Diabetes

Identifiers

PMID36634978
PMCPMC9843200

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.